Navigation Links
CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids
Date:1/19/2008

ATLANTA, Jan. 20 /PRNewswire/ -- CeloNova BioSciences, Inc. ("CeloNova"), leading and accelerating healthcare solutions through the provision and development of innovative medical devices, has released data from THE SPHERE, an 11 center, 8 country European study of uterine fibroid embolization using the Company's Embozene(TM) Microspheres. The study results were reported at the 20th Annual International Symposium on Endovascular Therapy.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080120/CLSU001 )

Patients in the study were followed for six months. According to one of the Principal Investigators, Joachim Kettenbach, MD, Medical University of Vienna, "Technical success was achieved in 98% of the patients. The side- effects of fibroids such as pain and heavy menstrual bleeding were significantly reduced while the patients' quality of life improved substantially."

Embolization is a minimally invasive procedure for uterine fibroids during which an Interventional Radiologist injects microspheres through a tiny catheter to the site of the fibroid. The microspheres -- each about the size of a period at the end of this sentence -- block the blood flow to the fibroids causing them to atrophy. The procedure is an alternative for most women with fibroids to surgical procedures such as hysterectomy or myomectomy. Recovery time is measured in days rather than weeks.

CeloNova's Embozene(TM) Color-Advanced Microspheres are the only microspheres that are color-coded by size. They have a hydrogel center and an outer layer of the Company's proprietary coating, Polyzene(R)-F which enhances biocompatibility.

"From the beginning, CeloNova has operated on the principle that our products would give first-rate clinical outcomes for patients and meet the real-world needs of physicians," said Thomas A. Gordy, President and Chief Executive Officer. Gordy continued, "This study shows that Embozene(TM) Microspheres embody that philosophy; reducing patients' symptoms while improving their quality of life. Color-coding improves patient safety while simplifying the job of those performing the procedure."

About CeloNova BioSciences, Inc.

Headquartered in Newnan, near Atlanta, Georgia, CeloNova BioSciences, Inc., is a developer of novel medical devices based on the company's patented Polyzene(R)-F surface coating technology. Polyzene(R)-F is highly lubricious, anti-inflammatory, and bacterial-resistant making it an ideal surface treatment for implanted medical devices. The company's current product portfolio includes its Embozene(TM) Color-Advanced Microspheres and the CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F. Other innovative devices are currently in the company's developmental pipeline. For more information, please visit http://www.celonova.com.

Contact

Thomas A. Gordy

President and Chief Executive Officer

+1 770-502-0304


'/>"/>
SOURCE CeloNova BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
3. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
4. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
5. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
6. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
7. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
8. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
9. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... Research and Markets has announced the addition of ... Infrared, Mercury; Trend Indicator):Analysis By Region, By Country (2016-21)" report ... ... at a CAGR of 5.33% during 2016-2021 The strong ... with surging demand of digital thermometer. Apart from that, the downfall ...
(Date:2/22/2017)... 2017  Allergan plc (NYSE: AGN), a leading ... Gold sponsor of the Alzheimer,s Foundation of America,s ... tour commemorates AFA,s15 years of educating individuals about ... The tour will include AFA,s free Concepts in ... of the AFA Quilt to Remember. ...
(Date:2/22/2017)... -- According to a new market research report "Process Analytical ... Services (Analyzers, Probes & Sensors), End - User (Pharmaceutical Manufacturers, CRO & ... is poised to reach USD 3.30 Billion by 2021 from USD 1.77 ... Continue Reading ... ...
Breaking Medicine Technology:
(Date:2/22/2017)... CT (PRWEB) , ... February 22, 2017 , ... The ... and the 2017 Forecast —on Thursday, February 23, 2017, at 1:00 PM ET. A ... webinar is part of the Interactive Webinar Series. , If you want to find ...
(Date:2/22/2017)... ... February 22, 2017 , ... FPS is a nonprofit mental ... Established in 1977, our organization was at the forefront in working with veterans ... life were evident and served as the catalyst for the establishing the agency. ...
(Date:2/22/2017)... Wis (PRWEB) , ... February 22, 2017 , ... ... a category by itself - the Vector™ Series Multi-Cook Oven offers up to ... oven chamber, featuring exclusive Structured Air Technology™ for unmatched evenness in cooking. Alto-Shaam ...
(Date:2/21/2017)... ... February 21, 2017 , ... Robins & Morton ... Durant, Oklahoma, on Feb. 21. , The celebration began with a ribbon cutting ... employees, the construction team and tribal leadership. , Choctaw Nation Durant Regional ...
(Date:2/21/2017)... , ... February 21, 2017 , ... As recently as ... according to the American Society of Plastic Surgeons. Some patients want to make a ... of their nose and improve their breathing ability. The team at usrhinoplasty.org ...
Breaking Medicine News(10 mins):